Low-frequency KRAS mutations are prevalent in lung adenocarcinomas.
作者： Meagan B Myers , Karen L McKim , Fanxue Meng , Barbara L Parsons
DOI: 10.2217/PME.14.69
关键词:
摘要: Aim: This study quantified low-frequency KRAS mutations in normal lung and adenocarcinomas, to understand their potential significance the development of acquired resistance EGFR-targeted therapies. Materials & methods: Allele-specific Competitive Blocker-PCR was used quantify codon 12 GAT (G12D) GTT (G12V) mutation 19 21 adenocarcinoma samples. Results: Lung adenocarcinomas had geometric mean mutant fractions 1.94 × 10-4 1.16 10-3, respectively. For 76.2% level greater than upper 95% confidence interval that lung. Conclusion: tumor subpopulations, not detectable by DNA sequencing, may drive EGFR blockade patients.
sci-hub.se 参考文章(58)
Barbara L Parsons, Meagan B Myers, Personalized cancer treatment and the myth of KRAS wild-type colon tumors Discovery Medicine. ,vol. 15, pp. 259- 267 ,(2013)
Brian G Blair, Alberto Bardelli, Ben Ho Park, Somatic alterations as the basis for resistance to targeted therapies. The Journal of Pathology. ,vol. 232, pp. 244- 254 ,(2014) , 10.1002/PATH.4278
Maela Del Grammastro, Mariagrazia Sciarrotta, Sara Malatesta, Carmen Nuzzo, Giovanna Finocchiaro, Bruno Perrucci, Donatella Carlone, Alain J. Gelibter, Anna Ceribelli, Andrea Mezzetti, Stefano Iacobelli, Francesco Cognetti, Fiamma Buttitta, Antonio Marchetti, Michele Milella, Lara Felicioni, Federico Cappuzzo, Luciana Irtelli, Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones Neoplasia. ,vol. 11, pp. 1084- 1092 ,(2009) , 10.1593/NEO.09814
James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco, Alberto M. Martelli, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Oncotarget. ,vol. 3, pp. 1068- 1111 ,(2012) , 10.18632/ONCOTARGET.659
Meagan B. Myers, Karen L. McKim, Barbara L. Parsons, A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid. Molecular Carcinogenesis. ,vol. 53, pp. 159- 167 ,(2014) , 10.1002/MC.21953
P Keohavong, H H Mady, W M Gao, J M Siegfried, J D Luketich, M F Melhem, Topographic analysis of K-ras mutations in histologically normal lung tissues and tumours of lung cancer patients British Journal of Cancer. ,vol. 85, pp. 235- 241 ,(2001) , 10.1054/BJOC.2001.1913
Janakiraman Subramanian, Daniel Morgensztern, Boone Goodgame, Maria Q. Baggstrom, Feng Gao, Jay Piccirillo, Ramaswamy Govindan, Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. Journal of Thoracic Oncology. ,vol. 5, pp. 23- 28 ,(2010) , 10.1097/JTO.0B013E3181C41E8D
Sabrina Arena, Claudio Isella, Miriam Martini, Ario de Marco, Enzo Medico, Alberto Bardelli, Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers Cancer Research. ,vol. 67, pp. 8468- 8476 ,(2007) , 10.1158/0008-5472.CAN-07-1126
Hiroko Endo, Jiro Okami, Hiroaki Okuyama, Toru Kumagai, Junji Uchida, Jumpei Kondo, Tetsuo Takehara, Yasuko Nishizawa, Fumio Imamura, Masahiko Higashiyama, Masahiro Inoue, Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation. Journal of Thoracic Oncology. ,vol. 8, pp. 131- 139 ,(2013) , 10.1097/JTO.0B013E3182779CCF
Chen Mao, Li-Xin Qiu, Ru-Yan Liao, Fang-Bing Du, Hong Ding, Wan-Chun Yang, Jin Li, Qing Chen, None, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies Lung Cancer. ,vol. 69, pp. 272- 278 ,(2010) , 10.1016/J.LUNGCAN.2009.11.020